The estimated Net Worth of Steven Pfanstiel is at least $174 Tausend dollars as of 5 August 2024. Mr Pfanstiel owns over 4,657 units of Marinus Pharmaceuticals Inc stock worth over $110,884 and over the last 3 years he sold MRNS stock worth over $62,840.
Mr has made over 3 trades of the Marinus Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 4,657 units of MRNS stock worth $5,262 on 5 August 2024.
The largest trade he's ever made was selling 4,657 units of Marinus Pharmaceuticals Inc stock on 5 August 2024 worth over $5,262. On average, Mr trades about 1,319 units every 46 days since 2021. As of 5 August 2024 he still owns at least 79,773 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Mr Pfanstiel stock trades at the bottom of the page.
Steven E. Pfanstiel C.M.A., M.B.A. is the CFO & Treasurer at Marinus Pharmaceuticals Inc.
Mr A is 48, he's been the CFO & Treasurer of Marinus Pharmaceuticals Inc since . There are 13 older and 1 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..
Steven's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... und Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: